Forte Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBRX Nasdaq 2836 www.fortebiorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Forte Biosciences, Inc.

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - Feb 9th, 2026 2:01 pm
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock - Jan 4th, 2026 5:32 am
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Dec 22nd, 2025 2:01 pm
Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year - Dec 12th, 2025 6:02 am
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update - Nov 14th, 2025 7:00 am
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Oct 3rd, 2025 2:01 pm
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Sep 15th, 2025 7:00 am
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely - Sep 11th, 2025 5:13 am
This Forte Biosciences Insider Increased Their Holding By 273% Last Year - Aug 15th, 2025 4:11 am
Forte Biosciences, Inc. Announces Results and Provides Update - Aug 14th, 2025 2:01 pm
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Jul 5th, 2025 6:09 am
Top Midday Decliners - Jun 25th, 2025 12:44 pm
Forte Biosciences Announces Pricing of $75 Million Public Offering - Jun 24th, 2025 10:28 pm
Forte Biosciences Announces Proposed Public Offering - Jun 24th, 2025 2:01 pm
Forte Biosciences announces data from trial in celiac disease for FB102 - Jun 24th, 2025 11:06 am
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - Jun 23rd, 2025 5:18 am
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Apr 1st, 2025 4:51 am
Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Mar 31st, 2025 7:00 am
One Forte Biosciences Insider Raised Stake By 273% In Previous Year - Feb 19th, 2025 3:51 am